Consort Medical, parent company of device developer and manufacturer Bespak, reports “strong volume growth” for Bespak’s inhaler business for the six months ending October 31, 2011. Bespak revenues were up 17% from 2010, with operating profits up 24%. The company also announced a new contract for a nicotine delivery device to be distributed by a subsidiary of British American Tobacco.
Bespak will scale up and manufacture the nicotine delivery device, which was developed by UK inhalation technology company Kind Consumer. The company anticipates that the “cigarette-like device” will launch in 2014, subject to approval by the MHRA and says that it has already obtained a clinical trial manufacture license from the agency.
Consort also announced that Bespak has been awarded a third dose counter line by GSK, with a planned start by mid-2012.
Read the Consort press release.
